Monoclonal Antibodies: A Prospective and Retrospective View
Abstract
Background: Monoclonal Antibodies (mAbs) represent one of the most important classes of biotherapeutic agents. They are used to cure many diseases, including cancer, autoimmune diseases, cardiovascular diseases, angiogenesis-related diseases and, more recently also haemophilia. They can be highly varied in terms of format, source, and specificity to improve efficacy and to obtain more targeted applications. This can be achieved by leaving substantially unchanged the basic structural components for paratope clustering. Objectives: The objective was to trace the most relevant findings that have deserved prestigious awards over the years, to report the most important clinical applications and to emphasize their latest emerging therapeutic trends. Results: We report the most relevant milestones and new technologies adopted for antibody development. Recent efforts in generating new engineered antibody-based formats are briefly reviewed. The most important antibody-based molecules that are (or are going to be) used for pharmacological practice have been collected in useful tables. Conclusions: The topics here discussed prove the undisputed role of mAbs as innovative biopharmaceuticals molecules and as vital components of targeted pharmacological therapies.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most antibody fragments and antibody-like molecules are non-glycosylated and can be more conveniently prepared in E. coli-based expression platforms.
“While full-length antibodies require mammalian expression systems due to the occurrence of functionally and structurally important glycosylations, most antibody fragments and antibody-like molecules are non-glycosylated and can be more conveniently prepared in E. coli-based expression platforms.”
From Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (2020) · cites this paper as [3]
Cites
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · see citing works
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309 · see citing works
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · see citing works
Commonality despite exceptional diversity in the baseline human antibody repertoire
Briney, B., Inderbitzin, A., Joyce, C., & Burton, D. R. (2019) · Nature · doi:10.1038/s41586-019-0879-y · Cited by 544 · see citing works
Holz, F. G., Amoaku, W., Donate, J., Guymer, R. H., Kellner, U., Schlingemann, R. O., Weichselberger, A., & Staurenghi, G. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2010.12.019 · Cited by 413 · see citing works
Pardi, N., Secreto, A. J., Shan, X., Debonera, F., Glover, J., Yi, Y., Muramatsu, H., Ni, H., Mui, B. L., Tam, Y. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms14630 · Cited by 352 · see citing works
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies
Wang, X., Das, T. K., Singh, S. K., & Kumar, S. (2009) · mAbs · doi:10.4161/mabs.1.3.8035 · Cited by 198 · see citing works
mRNA mediates passive vaccination against infectious agents, toxins, and tumors
Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707678 · Cited by 166 · see citing works
Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria
Robinson, M.-P., Ke, N., Lobstein, J., Peterson, C., Szkodny, A., Mansell, T. J., Tuckey, C., Riggs, P. D., Colussi, P. A., Noren, C. J., et al. (2015) · Nature Communications · doi:10.1038/ncomms9072 · Cited by 131 · see citing works
Prediction of site-specific interactions in antibody–antigen complexes: the proABC method and server
Olimpieri, P. P., Chailyan, A., Tramontano, A., & Marcatili, P. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt369 · Cited by 90 · see citing works
Krawczyk, K., Baker, T., Shi, J., & Deane, C. M. (2013) · Protein Engineering Design and Selection · doi:10.1093/protein/gzt043 · Cited by 87 · see citing works
Phillips, A. A., Fields, P. A., Hermine, O., Ramos, J. C., Beltran, B. E., Pereira, J., Wandroo, F., Feldman, T., Taylor, G. P., Sawas, A., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.205096 · Cited by 70 · see citing works
Rapid Generation of Monoclonal Antibodies from Single B Cells by Ecobody Technology
Ojima-Kato, T., Morishita, S., Uchida, Y., Nagai, S., Kojima, T., & Nakano, H. (2018) · Antibodies · doi:10.3390/antib7040038 · Cited by 23 · see citing works
Rezaie, F., Davami, F., Mansouri, K., Agha Amiri, S., Fazel, R., Mahdian, R., Davoudi, N., Enayati, S., Azizi, M., & Khalaj, V. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13483 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments
Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176324 · Cited by 134 · see citing works
“coli prokaryotic expression systems which enable easier production and with low costs compared to other available expression platforms like yeasts, insect cell lines, mammalian cells and transgenic plants and animals [3].”
BackgroundSelf-citation
- Authors
- Sivaccumar, J., Sandomenico, A., Vitagliano, L., & Ruvo, M.
- Affiliations
- Institute of Biostructure and Bioimaging (IT)
- Corresponding author
- Sivaccumar, Jwala
- Sandomenico, Annamaria
- Ruvo, Menotti
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2021-03
- Volume
- 28
- Issue
- 3
- Pages
- 435-471
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W3007167227
- Cited by
- 14
- References
- 14
- Citations by year
- 2025: 3 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 2
- FWCI
- 0.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MIUR (20155ACHBN, 2015783N45)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- monoclonal antibodies, antibody engineering, therapeutic antibodies, biopharmaceuticals, targeted therapy
- MeSH terms
- Antibodies, Monoclonal, Biological Products, Humans, Prospective Studies, Retrospective Studies, Protein Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
